Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Peter C TaylorTsutomu TakeuchiGerd-Rüdiger R BurmesterPatrick DurezJosef S SmolenWalter DeberdtMaher IssaJorge Ross TerresNatalia BelloKevin L WinthropPublished in: Annals of the rheumatic diseases (2021)
NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT02265705, NCT01721044, NCT01721057, NCT01711359 and NCT01885078.